H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating on Cesca Therapeutics (KOOL – Research Report) today and set a price target of $6.50. The company’s shares closed last Monday at $3.
According to TipRanks.com, Ramakanth is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -11.7% and a 27.4% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Zomedica Pharmaceuticals Corp, IntelGenx Technologies, and Gritstone Oncology Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Cesca Therapeutics with a $6.50 average price target.
Based on Cesca Therapeutics’ latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $1.87 million. In comparison, last year the company had a GAAP net loss of $26.66 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Cesca Therapeutics, Inc. engages in the research, development, commercialization and marketing of automated technologies for cell-based therapies for use in regenerative medicine. It operates through the following segments: Device and Clinical Development.